- Home
- IOR vs CLSD Comparison
IOR vs CLSD Comparison
Compare IOR & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- CLSD
- Stock Information
- Founded
- IOR 1984
- CLSD 2011
- Country
- IOR United States
- CLSD United States
- Employees
- IOR N/A
- CLSD N/A
- Industry
- IOR Real Estate Investment Trusts
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- IOR Real Estate
- CLSD Health Care
- Exchange
- IOR Nasdaq
- CLSD Nasdaq
- Market Cap
- IOR 72.8M
- CLSD 68.4M
- IPO Year
- IOR N/A
- CLSD 2016
- Fundamental
- Price
- IOR $18.68
- CLSD $0.42
- Analyst Decision
- IOR
- CLSD Hold
- Analyst Count
- IOR 0
- CLSD 4
- Target Price
- IOR N/A
- CLSD $4.33
- AVG Volume (30 Days)
- IOR 311.0
- CLSD 12.9M
- Earning Date
- IOR 08-07-2025
- CLSD 08-08-2025
- Dividend Yield
- IOR N/A
- CLSD N/A
- EPS Growth
- IOR N/A
- CLSD N/A
- EPS
- IOR 1.06
- CLSD N/A
- Revenue
- IOR N/A
- CLSD $4,166,000.00
- Revenue This Year
- IOR N/A
- CLSD $78.37
- Revenue Next Year
- IOR N/A
- CLSD $17.79
- P/E Ratio
- IOR $17.69
- CLSD N/A
- Revenue Growth
- IOR N/A
- CLSD N/A
- 52 Week Low
- IOR $16.01
- CLSD $0.29
- 52 Week High
- IOR $19.69
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- IOR 51.14
- CLSD 39.95
- Support Level
- IOR $18.02
- CLSD $0.40
- Resistance Level
- IOR $18.89
- CLSD $0.47
- Average True Range (ATR)
- IOR 0.18
- CLSD 0.06
- MACD
- IOR -0.01
- CLSD 0.01
- Stochastic Oscillator
- IOR 79.38
- CLSD 26.87
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. The business of the company is managed by Pillar Income Asset Management, Inc. The company's activities include locating, evaluating and recommending investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.